GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Inventories, Other

SELLAS Life Sciences Group (FRA:RXK3) Inventories, Other : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. SELLAS Life Sciences Group's other inventories for the quarter that ended in Jun. 2024 was €0.00 Mil.


SELLAS Life Sciences Group Inventories, Other Historical Data

The historical data trend for SELLAS Life Sciences Group's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Inventories, Other Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines